Abbott Laboratories Completes Acquisition of Exact Sciences, Strengthens Market Position
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowOn March 23, 2026, Abbott Laboratories (NYSE: ABT) completed the acquisition of Exact Sciences, positioning itself as a leader in the cancer screening and diagnostics market. This acquisition adds a significant growth vertical to Abbott's high-single-digit growth outlook and aims to address a $60 billion U.S. market focused on cancer screening and precision oncology diagnostics. Following the acquisition, Exact Sciences has become a wholly-owned subsidiary of Abbott Laboratories. This strategic move highlights Abbott's commitment to enhancing early cancer detection and personalized treatment options.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Abbott Laboratories (ABT)
Abbott Laboratories is a diversified healthcare company spanning diagnostics, medical devices, and nutrition.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier ABT news
ABT stock page and all news →Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
